USFDA approves commercial production of Vasostrict at Endo newest Indore facility
Malvern: Endo, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved commercial production of VASOSTRICT (vasopressin injection, USP) at the company's newest 20,000-square-foot aseptic manufacturing facility in Indore, India.
"This is a significant milestone for Endo as we invest and innovate in our sterile injectables business," said Scott Hirsch, Interim CEO of Endo. "The FDA approval of our newest manufacturing site demonstrates our commitment to meeting product demand and delivering quality medicines to patients."
Endo is a speciality pharmaceutical company focusing on developing and delivering life-enhancing products—many of which are complex in nature and require unique expertise, technology, and equipment. It focuses on medical therapeutics, specifically in the areas of urology, orthopedics, and endocrinology, and on sterile injectables for hospitals and health systems, along with generics.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.